GoodRx says Q1 and Q2 2026 financial statements should not be relied upon
GDRX•GoodRx said its Q1 and Q2 2026 financial statements should not be relied upon and that it expects material weaknesses in internal control for both quarters, according to an SEC filing.
1. SEC filing
GoodRx said its Q1 and Q2 2026 financial statements should not be relied upon. The company also expects material weaknesses in internal control for both quarters.
